Combined Application of Aminoglycosides and Ascorbic Acid in the Elimination of Proteus mirabilis Rods Responsible for Causing Catheter-Associated Urinary Tract Infections (CAUTIs)-A Molecular Approach

Int J Mol Sci. 2022 Oct 28;23(21):13069. doi: 10.3390/ijms232113069.

Abstract

Proteus mirabilis is a common cause of catheter-associated urinary tract infections (CAUTIs). In this study, we verified the effectiveness of amikacin or gentamicin and ascorbic acid (AA) co-therapy in eliminating uropathogenic cells, as well as searched for the molecular basis of AA activity by applying chromatographic and fluorescent techniques. Under simulated physiological conditions, a combined activity of the antibiotic and AA supported the growth (threefold) of the P. mirabilis C12 strain, but reduced catheter colonization (≤30%) in comparison to the drug monotherapy. Slight modifications in the phospholipid and fatty acid profiles, as well as limited (≤62%) 2',7'-dichlorofluorescein fluorescence, corresponding to the hydroxyl radical level, allowed for the exclusion of the hypothesis that the anti-biofilm effect of AA was related to membrane perturbations of the C12 strain. However, the reduced (≤20%) fluorescence intensity of propidium iodide, as a result of a decrease in membrane permeability, may be evidence of P. mirabilis cell defense against AA activity. Quantitative analyses of ascorbic acid over time with a simultaneous measurement of the pH values proved that AA can be an effective urine acidifier, provided that it is devoid of the presence of urease-positive cells. Therefore, it could be useful in a prevention of recurrent CAUTIs, rather than in their treatment.

Keywords: Proteus mirabilis; adhesion; aminoglycosides; ascorbic acid; catheter; fatty acids; hydroxyl radical; membrane permeability; phospholipids.

MeSH terms

  • Aminoglycosides / metabolism
  • Anti-Bacterial Agents / metabolism
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Ascorbic Acid / metabolism
  • Ascorbic Acid / pharmacology
  • Biofilms
  • Catheters
  • Humans
  • Proteus Infections* / drug therapy
  • Proteus mirabilis / metabolism
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / pathology
  • Urinary Tract Infections* / prevention & control

Substances

  • Aminoglycosides
  • Ascorbic Acid
  • Anti-Bacterial Agents

Grants and funding

This research received no external funding. It was supported by the Department of Biology of Bacteria (University of Lodz, Lodz, Poland).